|
|
COX-2 Inhibitor Plus PPI Best for Preventing NSAID-Related Gastropathy
|
| Link ID |
5720 |
| Title |
COX-2 Inhibitor Plus PPI Best for Preventing NSAID-Related Gastropathy |
| Url |
http://www.medscape.com/viewarticle/574428?src=rss |
| Description |
Although all of the common gastroprotective strategies reduce the risk of upper gastrointestinal (GI) complications in users of nonsteroidal anti-inflammatory drugs (NSAIDs), the combination of a COX-2 inhibitor with a proton pump inhibitor (PPI) is associated with the largest risk reduction, according to a Canadian study reported in the April issue of Gastroenterology. Reuters Health Information |
| Category |
Articles > Gastroenterology |
| Keywords |
|
| Date |
May 14, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Gastroenterology |
| 2. |
Celiac Disease Patients Now Typically Asymptomatic at Diagnosis
|
|
|
With the advent of modern screening tests and increased awareness of celiac disease, the clinical profile of newly diagnosed pediatric patients has changed, physicians in Milwaukee report. Most are school-age and asymptomatic, having been referred for screening on the basis of their high-risk status. Reuters Health Information
|
| 4. |
Ursodeoxycholic Acid Might Help in Refractory HCV
|
|
|
Ursodeoxycholic acid (UDCA) may be of use in treatment of patients with chronic hepatitis C virus (HCV) who do not respond to therapy with combined pegylated interferon and ribavirin, Japanese researchers report in the December issue of Gut. Reuters Health Information
|
| 5. |
Cannabinoid-Blocking Agents May Fight Alcoholic Fatty Liver
|
|
|
Studies in mice provide evidence that endogenous cannabinoids are involved in the development of alcohol-induced fatty liver disease and that blocking these proteins might help fight alcoholic fatty liver disease. Reuters Health Information
|
|
|
